The COBRE in Lipidomics continues to evolve from basic science studies to animal models and now to translational research. This evolution requires continued advances in basic research, for example, in technology and ability to develop biomarkers. It also requires attracting translational scientists to Lipidomics and/or enabling Lipidomics investigators to conduct translational research through retooling, collaborating to move their investigations from the bench toward clinical application. The Center in Lipidomics and Pathobiology at MUSC builds on substantial accomplishments during the first two phases of the COBRE, including mentoring of 19 targeted junior faculty investigators and participation by ~30 MUSC research faculty in COBRE activities. The COBRE has also been very successful in recruiting minorities and women as target faculty. Many of these successes were enabled through the granting of Pilot Projects to promising investigators. Therefore, the overall goal of this program is to continue the significant momentum we have gained from the previous funding cycles by providing and prioritizing short-term funding for translational and other pilot studies designed to determine expeditiously whether a novel idea or technology has sufficient merit and feasibility to move forward and become the basis of a competitive NIH research project grant application. To this end, we will build on and modify informatics tools and web resources developed and maintained by the South Carolina Clinical and Translational Institute (SCTR) that serve as CTSA-supported infrastructure to develop a platform for electronic submission and review of applications and progress reports for COBRE Pilot Projects Programs. A request for applications (RFA) will be advertised annually. Pilot project investigators may request up to $50,000/yr (up to a total of $100,000 direct costs) for a maximum of two years (24 months). Progress reports will be required at 6-month Intervals with a final report at the end of the designated project period. Second-year support, if requested, will be contingent on productivity. The goals of this Pilot Projects Program will be successfully met by: Increasing the number and competitiveness of translationally based publications and grant proposals in the field of Lipidomics and Pathobiology submitted to NIH and other biomedical research sponsors; strengthening the resources and competitiveness of MUSC to conduct basic, translational and clinical research in the field of Lipidomics and Pathobiology; and consolidating the stature of our Center in Lipidomics and Pathobiology as a nationally and internationally recognized, unique center of excellence in basic and translational studies In Lipidomics and Pathobiology.

Public Health Relevance

This proposal is to support several unique core resources that significantly enhance research on novel bioactive lipids that are involved in many important diseases including cancer, neurodegeneration, diabetes and cardiovascular disease. Moreover, the research has significant impact on drug discovery and innovative biomedical industry that will benefit the economy of SC.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Center Core Grants (P30)
Project #
5P30GM103339-04
Application #
8883583
Study Section
Special Emphasis Panel (ZRR1)
Project Start
2015-07-01
Project End
2016-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
4
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800
Fekry, Baharan; Jeffries, Kristen A; Esmaeilniakooshkghazi, Amin et al. (2018) C16-ceramide is a natural regulatory ligand of p53 in cellular stress response. Nat Commun 9:4149
Kim, Myung Jong; Jeon, Sohee; Burbulla, Lena F et al. (2018) Acid ceramidase inhibition ameliorates ?-synuclein accumulation upon loss of GBA1 function. Hum Mol Genet 27:1972-1988
Helke, Kristi; Angel, Peggi; Lu, Ping et al. (2018) Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. Sci Rep 8:1627
Gencer, Salih; Oleinik, Natalia; Kim, Jisun et al. (2017) TGF-? receptor I/II trafficking and signaling at primary cilia are inhibited by ceramide to attenuate cell migration and tumor metastasis. Sci Signal 10:
Bai, Aiping; Mao, Cungui; Jenkins, Russell W et al. (2017) Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase. PLoS One 12:e0177805
Kim, Soohyun P; Frey, Julie L; Li, Zhu et al. (2017) Lack of Lrp5 Signaling in Osteoblasts Sensitizes Male Mice to Diet-Induced Disturbances in Glucose Metabolism. Endocrinology 158:3805-3816
Scheffel, Matthew J; Helke, Kristi; Lu, Ping et al. (2017) Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis. Sci Rep 7:15552
Ghatak, Shibnath; Markwald, Roger R; Hascall, Vincent C et al. (2017) Transforming growth factor ?1 (TGF?1) regulates CD44V6 expression and activity through extracellular signal-regulated kinase (ERK)-induced EGR1 in pulmonary fibrogenic fibroblasts. J Biol Chem 292:10465-10489
Ghatak, Shibnath; Hascall, Vincent C; Markwald, Roger R et al. (2017) Transforming growth factor ?1 (TGF?1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis. J Biol Chem 292:10490-10519

Showing the most recent 10 out of 21 publications